About: Biological therapy and the immune system in patients with chronic myeloid leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Biological therapy and the immune system in patients with chronic myeloid leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells that has been recognized as a disease responsive to immunotherapy. Despite the huge success of the tyrosine kinase inhibitors (TKIs), CML remains for the most part incurable, probably due to treatment resistance of leukemic stem cells, which are responsible for rapid disease relapse after discontinuation of therapy. Only allogeneic stem cell transplantation enables disease eradication. In addition to the Bcr-Abl1 oncoprotein, TKIs also inhibit off-target kinases (e.g. c-kit, Src, Tec), some of them having physiological functions in immune responses. In vitro studies have implied immunomodulatory effects of TKIs and interferon-alpha (IFN-a), but comprehensive information from in vivo analyses is missing. This review summarizes the recent advances in the field of immunology of CML, including basic information about leukemia-associated antigens and peptide vaccines, that could lead to the incorporation of TKIs and IFN-a in future therapeutic, potentially curative, interventions for CML. Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells that has been recognized as a disease responsive to immunotherapy. Despite the huge success of the tyrosine kinase inhibitors (TKIs), CML remains for the most part incurable, probably due to treatment resistance of leukemic stem cells, which are responsible for rapid disease relapse after discontinuation of therapy. Only allogeneic stem cell transplantation enables disease eradication. In addition to the Bcr-Abl1 oncoprotein, TKIs also inhibit off-target kinases (e.g. c-kit, Src, Tec), some of them having physiological functions in immune responses. In vitro studies have implied immunomodulatory effects of TKIs and interferon-alpha (IFN-a), but comprehensive information from in vivo analyses is missing. This review summarizes the recent advances in the field of immunology of CML, including basic information about leukemia-associated antigens and peptide vaccines, that could lead to the incorporation of TKIs and IFN-a in future therapeutic, potentially curative, interventions for CML. (en)
Title	Biological therapy and the immune system in patients with chronic myeloid leukemia Biological therapy and the immune system in patients with chronic myeloid leukemia (en)
skos:prefLabel	Biological therapy and the immune system in patients with chronic myeloid leukemia Biological therapy and the immune system in patients with chronic myeloid leukemia (en)
skos:notation	RIV/61989592:15110/12:33142810!RIV13-MZ0-15110___
http://linked.open...avai/riv/aktivita	P S
http://linked.open...avai/riv/aktivity	P(NT12218), S
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Rohoň, Peter
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	125083
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/12:33142810
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	immunomodulation; interferon-alpha; tyrosine kinase inhibitors; leukemia-associated antigens; chronic myeloid leukemia (en)
http://linked.open.../riv/klicoveSlovo	tyrosine kinase inhibitors leukemia-associated antigens chronic myeloid leukemia immunomodulation interferon-alpha
http://linked.open...odStatuVydavatele	JP - Japonsko
http://linked.open...ontrolniKodProRIV	[737B6D3ED559]
http://linked.open...i/riv/nazevZdroje	International Journal of Hematology
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	1 (xsd:int)
http://linked.open...vavai/riv/projekt	Personalized treatment of chronic myeloproliferative disorders and myelodysplastic syndrome - a cellular metabolomics study.
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	96
http://linked.open...iv/tvurceVysledku	Rohoň, Peter
issn	0925-5710
number of pages	9 (xsd:int)
http://bibframe.org/vocab/doi	10.1007/s12185-012-1116-8
http://localhost/t...ganizacniJednotka	15110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software